IJCRR - 5(13), July, 2013
Pages: 69-73
RHINOLITH ASSOCIATED WITH LONG-TERM TOPIRAMATE THERAPY IN ALCOHOL WITHDRAWAL PATIENTS
Author: Suvendu Narayan Mishra, Monalisa Jena, Swati Mishra, S.S.G. Mohapatra
Category: Healthcare
[Download PDF]
Abstract:
Topiramate, a commonly used drug in the management of seizures and migraine headache, can increase the risk of calcium phosphate kidney stones. However, specific side effects are nausea, anorexia, parasthesia, memory problems etc. We report a case of 54 year old male patient with alcohol withdrawal syndrome treated with bupropion, disulfiram, topiramate, chlordiazepoxide. After one year of treatment, the patient developed nephrolithiasisand rhinolith on right side which was confirmed by USG and CT scan respectively. As all other drugs except topiramate do not have any tendency to form stones, the most probable drug may be topiramate. ENT specialists should be aware of this possible complication to undertake early interventions.
Keywords: Topiramate, Alcohol withdrawal syndrome, Disulfiram, Rhinolith, Bupropion
Citation:
Suvendu Narayan Mishra, Monalisa Jena, Swati Mishra, S.S.G. Mohapatra. RHINOLITH ASSOCIATED WITH LONG-TERM TOPIRAMATE THERAPY IN ALCOHOL WITHDRAWAL PATIENTS International Journal of Current Research and Review. 5(13), July, 69-73
References:
1. Maryanoff, BE; Nortey, SO; Gardocki, JF; Shank, RP; Dodgson, SP (1987). "Anticonvulsant O-alkyl sulfamates. 2,3:4,5- Bis-O-(1-methylethylidene)-beta-Dfructopyranose sulfamate and related compounds". Journal of Medical Chemistry 30 (5): 880–7.
2. Maryanoff, BE; Costanzo, MJ; Nortey, SO; Greco, MN; Shank, RP; Schupsky, JJ; Ortegon, MP; Vaught, JL (1998). "Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives". Journal of Medical Chemistry 41 (8): 1315–43.
3. Arnone, D (2005). "Review of the use of Topiramate for treatment of psychiatric disorders". Annals of general psychiatry 4 (1): 5.
4. Johnson, BA; Ait-Daoud, N; Bowden, CL; Diclemente, CC; Roache, JD; Lawson, K; Javors, MA; Ma, JZ (2003). "Oral topiramate for treatment of alcohol dependence: a randomised controlled trial". Lancet 361 (9370): 1677–85
5. Johnson, BA; Rosenthal, N; Capece, JA; Wiegand, F; Mao, L; Beyers, K; McKay, A; Ait-Daoud, N et al. (2007). "Topiramate for treating alcohol dependence: a randomized controlled trial". JAMA: the Journal of the American Medical Association 298 (14): 1641–51.
6. "Medication can help recovering meth addicts stay sober, study finds". Retrieved 2012-06-13.
7. Van Ameringen, M; Mancini, C; Pipe, B; Campbell, M; Oakman, J (2002). "Topiramate treatment for SSRI-induced weight gain in anxiety disorders". The Journal of clinical psychiatry 63 (11): 981– 4.
8. Wilding, J; Van Gaal, L; Rissanen, A; Vercruysse, F; Fitchet, M; Obes-002 Study, Group (2004). "A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects". International journal of obesity and related metabolic disorders: journal of the International Association for the Study of Obesity 28 (11): 1399–410.
9. Shapira, NA; Goldsmith, TD; McElroy, SL (2000). "Treatment of binge-eating disorder with topiramate: a clinical case series". The Journal of clinical psychiatry 61 (5): 368–72
10. McElroy, SL; Arnold, LM; Shapira, NA; Keck Jr, PE; Rosenthal, NR; Karim, MR; Kamin, M; Hudson, JI (2003). "Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial". The American Journal of Psychiatry 160 (2): 255–61.
11. Mirza, Nasir; Marson, Anthony G.; Pirmohamed, Munir (2009). "Effect of topiramate on acid-base balance: extent, mechanism and effects". British Journal of Clinical Pharmacology 68 (5): 655–61
12. Welch, Brian J.. MD; Graybeal, Dion, MD; Moe, Orson W., MD; Maalouf, Naim M., MD; Sakhee, Khashayar, MD. "Biochemical and Stone-Risk ProfilesWith Topiramate Treatment." Am J Kidney Dis 48:555-563.
13. Slemmer, Jennifer E.; Martin, Billy R.; Damaj, M. Imad (2000). "Bupropion Is a Nicotinic Antagonist". The Journal of Pharmacology and Experimental Therapeutics 295 (1): 321–7.
14. Terry, P.; Katz, Jonathan L. (1997). "Dopaminergic mediation of the discriminative stimulus effects of bupropion in rats". Psychopharmacology 134 (2): 201– 12.
15. Learned-Coughlin, Susan M; Bergström, Mats; Savitcheva, Irina; Ascher, John; Schmith, Virginia D; Långstrom, Bengt (2003). "In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography". Biological Psychiatry 54 (8): 800–5.
16. Fryer, John D.; Lukas, Ronald J. (1999). "Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine". The Journal of Pharmacology and Experimental Therapeutics 288 (1): 88–92.
17. Fava, Maurizio; Rush, A. John; Thase, Michael E.; Clayton, Anita; Stahl, Stephen M.; Pradko, James F.; Johnston, J. Andrew (2005). "15 Years of Clinical Experience with Bupropion HCl". The Primary Care Companion to the Journal of Clinical Psychiatry 07 (3): 106–13.
18. Emmanuel, Naresh P.; Brawman-Mintzer, Olga; Morton, W. Alexander; Book, Sarah W.; Johnson, Michael R.; Lorberbaum, Jeffrey P.; Ballenger, James C.; Lydiard, R. Bruce (2000). "Bupropion-SR in treatment of social phobia". Depression and Anxiety 12 (2): 111–3.
19. Klonoff, DC; Greenway, F (2008). "Drugs in the pipeline for the obesity market". Journal of diabetes science and technology 2 (5): 913–8
20. Cantwell, DP (1998). "ADHD through the life span: The role of bupropion in treatment". The Journal of clinical psychiatry 59 (Suppl 4): 92–4.
21. Kampman, KM (2008). "The search for medications to treat stimulant dependence". Addiction science and clinical practice 4 (2): 28–35
22. Wright, Curtis; Moore, Richard D. (1990). "Disulfiram treatment of alcoholism". The American Journal of Medicine 88 (6): 647– 55.
23. "Disulfiram Side Effects". Drugs.com. Retrieved 6 November 2010.
24. Boukriche, Yassine; Weisser, Isabelle; Aubert, Pascale; Masson, Catherine (2000). "MRI findings in case of late onset disulfiram-induced neurotoxicity". Journal of Neurology 247 (9): 714–5.
25. Ghorayeb, Bechara (October 21, 2006). "Pictures of Rhinolith (Nasal Calculus)". Retrieved on December 10, 2006.
26. "Disulfiram Side Effects". Drugs.com. Retrieved 6 November 2010.
27. Boukriche, Yassine; Weisser, Isabelle; Aubert, Pascale; Masson, Catherine (2000). "MRI findings in case of late onset disulfiram-induced neurotoxicity". Journal of Neurology 247 (9): 714–5.
28. Balit, CR; Lynch, CN; Isbister, GK (2003). "Bupropion poisoning: A case series". The Medical journal of Australia 178 (2): 61–3.
29. Buckley, Nicholas A.; Faunce, Thomas A. (2003). "'Atypical' Antidepressants in Overdose: Clinical considerations with respect to safety". Drug Safety 26 (8): 539– 51.
30. Spiller, Henry A.; Ramoska, Edward A.; Krenzelok, Edward P.; Sheen, Sandra R.; Borys, Douglas J.; Villalobos, Daniel; Muir, Scott; Jones-Easom, Leslie (1994). "Bupropion overdose: A 3-year multi-center retrospective analysis". The American Journal of Emergency Medicine 12 (1): 43– 5
31. Van Melle, Joost P; De Jonge, Peter; Van Den Berg, Maarten P; Pot, Harm J; Van Veldhuisen, Dirk J (2006). "Treatment of Depression in Acute Coronary Syndromes with Selective Serotonin Reuptake Inhibitors". Drugs 66 (16): 2095–107.
32. Mainie, Inder; McGurk, Colm; McClintock, Gavin; Robinson, J (2001). "Seizures after buproprion overdose". The Lancet 357 (9268): 1624.
33. Welch, Brian J.. MD; Graybeal, Dion, MD; Moe, Orson W., MD; Maalouf, Naim M., MD; Sakhee, Khashayar, MD. "Biochemical and Stone-Risk ProfilesWith Topiramate Treatment." Am J Kidney Dis 48:555-563. doi:10.1053/j.ajkd.2006.07.003.
34. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther,1980; 30:239-4

|